United States - English - NLM (National Library of Medicine)

sandoz inc. - mometasone furoate monohydrate (unii: mtw0weg809) (mometasone - unii:8hr4qj6dw8) - mometasone furoate 50 ug - mometasone furoate monohydrate nasal spray is indicated for the treatment of the nasal symptoms of seasonal allergic and perennial allergic rhinitis, in adults and pediatric patients 2 years of age and older. mometasone furoate monohydrate nasal spray is indicated for the relief of nasal congestion associated with seasonal allergic rhinitis, in adults and pediatric patients 2 years of age and older. mometasone furoate monohydrate nasal spray is indicated for the prophylaxis of the nasal symptoms of seasonal allergic rhinitis in adult and adolescent patients 12 years and older. mometasone furoate monohydrate nasal spray is indicated for the treatment of nasal polyps in patients 18 years of age and older. mometasone furoate monohydrate nasal spray is contraindicated in patients with known hypersensitivity to mometasone furoate or any of its ingredients. risk summary there are no adequate and well-controlled clinical studies of mometasone furoate monohydrate nasal spray in pregnant women. in animal reproducti

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - mometasone furoate (unii: 04201gdn4r) (mometasone furoate - unii:04201gdn4r) - mometasone furoate 1 mg in 1 ml - mometasone furoate lotion (mometasone furoate topical solution usp 0.1%) is a medium potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. since safety and efficacy of mometasone furoate lotion (mometasone furoate topical solution usp 0.1%) have not been established in pediatric patients below 12 years of age, its use in this age group is not recommended. (see precautions - pediatric use ). mometasone furoate lotion (mometasone furoate topical solution usp 0.1%) is contraindicated in those patients with a history of hypersensitivity to any of the components in the preparation.

United States - English - NLM (National Library of Medicine)

harris pharmaceutical, inc. - mometasone furoate (unii: 04201gdn4r) (mometasone - unii:8hr4qj6dw8) - mometasone furoate 1 mg in 1 ml - mometasone furoate topical solution usp, 0.1% (lotion) is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 12 years of age or older. none. teratogenic effects pregnancy category c: there are no adequate and well-controlled studies in pregnant women. therefore, mometasone furoate topical solution usp, 0.1% (lotion) should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. when administered to pregnant rats, rabbits, and mice, mometasone furoate increased fetal malformations. the doses that produced malformations also decreased fetal growth, as measured by lower fetal weights and/or delayed ossification. mometasone furoate also caused dysto

United States - English - NLM (National Library of Medicine)

cosette pharmaceuticals, inc. - mometasone furoate (unii: 04201gdn4r) (mometasone - unii:8hr4qj6dw8) - mometasone furoate 1 mg in 1 ml - mometasone furoate topical solution usp, 0.1% (lotion) is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 12 years of age or older. mometasone furoate topical solution usp, 0.1% (lotion) is contraindicated in those patients with a history of hypersensitivity to any of the components in the preparation. teratogenic effects pregnancy category c: there are no adequate and well-controlled studies in pregnant women. therefore, mometasone furoate topical solution usp, 0.1% (lotion) should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. when administered to pregnant rats, rabbits, and

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - mometasone furoate monohydrate - unknown - mometasone furoate monohydrate adrenocorticoid-synthetic active 0.0 - active constituent

United States - English - NLM (National Library of Medicine)

e. fougera & co. a division of fougera pharmaceuticals inc. - mometasone furoate (unii: 04201gdn4r) (mometasone - unii:8hr4qj6dw8) - mometasone furoate 1 mg in 1 ml - mometasone furoate lotion (mometasone furoate topical solution 0.1%) is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 12 years of age or older. mometasone furoate lotion (mometasone furoate topical solution 0.1%) is contraindicated in those patients with a history of hypersensitivity to any of the components in the preparation. teratogenic effects, pregnancy category c: there are no adequate and well-controlled studies in pregnant women. therefore, mometasone furoate lotion (mometasone furoate topical solution 0.1%) should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. when administered to pregnant rats, rabbits, and mice, mometas

United States - English - NLM (National Library of Medicine)

merck sharp & dohme corp. - mometasone furoate monohydrate (unii: mtw0weg809) (mometasone - unii:8hr4qj6dw8) - mometasone furoate 50 ug - nasonex® is indicated for the treatment of the nasal symptoms of seasonal allergic and perennial allergic rhinitis, in adults and pediatric patients 2 years of age and older. nasonex is indicated for the relief of nasal congestion associated with seasonal allergic rhinitis, in adults and pediatric patients 2 years of age and older. nasonex is indicated for the prophylaxis of the nasal symptoms of seasonal allergic rhinitis in adult and adolescent patients 12 years and older. nasonex is indicated for the treatment of nasal polyps in patients 18 years of age and older. nasonex is contraindicated in patients with known hypersensitivity to mometasone furoate or any of its ingredients. risk summary there are no adequate and well-controlled clinical studies of nasonex in pregnant women. in animal reproduction studies with pregnant mice, rats, or rabbits, mometasone furoate caused increased fetal malformations and decreased fetal survival and growth following administration of doses that produced exposures appro

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - mometasone (unii: 8hr4qj6dw8) (mometasone - unii:8hr4qj6dw8) - mometasone 50 ug - mometasone furoate nasal spray 50 mcg is indicated for the treatment of the nasal symptoms of seasonal allergic and perennial allergic rhinitis, in adults and pediatric patients 2 years of age and older. mometasone furoate nasal spray 50 mcg is indicated for the relief of nasal congestion associated with seasonal allergic rhinitis, in adults and pediatric patients 2 years of age and older. mometasone furoate nasal spray 50 mcg is indicated for the prophylaxis of the nasal symptoms of seasonal allergic rhinitis in adult and adolescent patients 12 years and older. mometasone furoate nasal spray 50 mcg is indicated for the treatment of nasal polyps in patients 18 years of age and older. mometasone furoate nasal spray is contraindicated in patients with known hypersensitivity to mometasone furoate or any of its ingredients. teratogenic effects: pregnancy category c: there are no adequate and well-controlled studies in pregnant women. mometasone furoate nasal spray 50 mcg, like other corticosteroids, should be

United States - English - NLM (National Library of Medicine)

apotex corp. - mometasone (unii: 8hr4qj6dw8) (mometasone - unii:8hr4qj6dw8) - mometasone 50 ug - mometasone furoate nasal spray is indicated for the prophylaxis of the nasal symptoms of seasonal allergic rhinitis in adult and pediatric patients 12 years and older. mometasone furoate nasal spray is indicated for the treatment of chronic rhinosinusitis with nasal polyps in adult patients 18 years of age and older. mometasone furoate nasal spray is contraindicated in patients with known hypersensitivity to mometasone furoate or any of its ingredients [see warnings and precautions (5.3), description (11)]. risk summary mometasone is minimally absorbed systemically following nasal use, and maternal use is not expected to result in fetal exposure to the drug. available data from observational studies of mometasone use in pregnant women are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. in animal reproduction studies with pregnant mice, rats, or rabbits (subcutaneous, subcutaneous/topical dermal/oral, and topical dermal/oral, respectively), mometasone furoate caused increased fetal malformations and decreased fetal survival and growth following administration of doses that produced exposures approximately 1/3 to 8 times the maximum recommended human dose (mrhd) on a mcg/m2 or auc basis [see data]. however, experience with oral corticosteroids suggests that rodents are more prone to teratogenic effects from corticosteroid exposure than humans. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.  data animal data in an embryofetal development study with pregnant mice dosed throughout the period of organogenesis, mometasone furoate produced cleft palate at a dose less than the maximum recommended daily intranasal dose (mrdid) (on a mcg/m2 basis with maternal subcutaneous doses of 60 mcg/kg and above) and decreased fetal survival at approximately 2 times the mrdid (on a mcg/m2 basis with a maternal subcutaneous dose of 180 mcg/kg). no toxicity was observed with a dose that produced an exposure less than the mrdid (on a mcg/m2 basis with maternal topical dermal doses of 20 mcg/kg and above).  in an embryofetal development study with pregnant rats dosed throughout the period of organogenesis, mometasone furoate produced fetal umbilical hernia at exposures approximately 10 times the mrdid (on a mcg/m2 basis with maternal topical dermal doses of 600 mcg/kg and above) and delays in fetal ossification at a dose approximately 6 times the mrdid (on a mcg/m2 basis with maternal topical dermal doses of 300 mcg/kg and above).  in another reproductive toxicity study, pregnant rats were dosed with mometasone furoate throughout pregnancy or late in gestation. treated animals had prolonged and difficult labor, fewer live births, lower birth weight, and reduced early pup survival at a dose less than the mrdid (on a mcg/m2 basis with a maternal subcutaneous dose of 15 mcg/kg). there were no findings at a dose less than the mrdid (on a mcg/m2 basis with a maternal subcutaneous dose of 7.5 mcg/kg).  embryofetal development studies were conducted with pregnant rabbits dosed with mometasone furoate by either the topical dermal route or oral route throughout the period of organogenesis. in the study using the topical dermal route, mometasone furoate caused multiple malformations in fetuses (e.g., flexed front paws, gallbladder agenesis, umbilical hernia, hydrocephaly) at doses approximately 6 times the mrdid (on mcg/m2 basis with maternal topical dermal doses of 150 mcg/kg and above). in the study using the oral route, mometasone furoate caused increased fetal resorptions and cleft palate and/or head malformations (hydrocephaly and domed head) at a dose approximately 30 times of the mrdid (on a mcg/m2 basis with a maternal oral dose of 700 mcg/kg). at approximately 110 times the mrdid (on a mcg/m2 basis with a maternal oral dose of 2800 mcg/kg), most litters were aborted or resorbed. no effects were observed at a dose approximately 6 times the mrdid (on a mcg/m2 basis with a maternal oral dose of 140 mcg/kg). risk summary there are no available data on the presence of mometasone furoate nasal spray in human milk, the effects on the breastfed child, or the effects on milk production. however, mometasone is minimally absorbed systemically by the mother following nasal use, and breastfeeding is not expected to result in exposure of the infant to mometasone. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for mometasone furoate nasal spray and any potential adverse effects on the breastfed infant from mometasone furoate nasal spray or from the underlying maternal condition.  the safety and effectiveness of mometasone furoate nasal spray for prophylaxis of the nasal symptoms of seasonal allergic rhinitis in pediatric patients 12 years of age and older have been established [see adverse reactions (6.1) and clinical studies (14.1)]. use of mometasone furoate nasal spray forthis indication is supported by evidence from controlled trials in adult and pediatric patients 12 years of age and older [see clinical studies (14.1)].  the safety and effectiveness of mometasone furoate nasal spray for the treatment of chronic rhinosinusitis with nasal polyps in pediatric patients less than 18 years of age have not been established. effectiveness was not demonstrated in one 4-month trial conducted to evaluate the safety and efficacy of mometasone furoate nasal spray in the treatment of chronic rhinosinusitis with nasal polyps in pediatric patients 6 to 17 years of age. the primary objective of the study was to evaluate safety; efficacy parameters were collected as secondary endpoints. a total of 127 patients with chronic rhinosinusitis with nasal polyps were randomized to placebo or mometasone furoate nasal spray 100 mcg once or twice daily (patients 6 to 11 years of age) or 200 mcg once or twice daily (patients 12 to 17 years of age). the results of this trial did not support the efficacy of mometasone furoate nasal spray in the treatment of chronic rhinosinusitis with nasal polyps in pediatric patients. the adverse reactions reported in this trial were similar to the adverse reactions reported in patients 18 years of age and older with chronic rhinosinusitis with nasal polyps. effect of growth controlled clinical studies have shown nasal corticosteroids may cause a reduction in growth velocity in pediatric patients. this effect has been observed in the absence of laboratory evidence of hypothalamic-pituitary-adrenal (hpa) axis suppression, suggesting that growth velocity is a more sensitive indicator of systemic corticosteroid exposure in pediatric patients than some commonly used tests of hpa axis function. the long-term effects of this reduction in growth velocity associated with nasal corticosteroids, including the impact on final adult height, are unknown. the potential for "catch up" growth following discontinuation of treatment with nasal corticosteroids has not been adequately studied. the growth of pediatric patients receiving nasal corticosteroids, including mometasone furoate nasal spray, should be monitored routinely (e.g., via stadiometry). the potential growth effects of prolonged treatment should be weighed against clinical benefits obtained and the availability of safe and effective noncorticosteroid treatment alternatives. to minimize the systemic effects of nasal corticosteroids, including mometasone furoate nasal spray, each patient should be titrated to his/her lowest effective dose. a clinical study to assess the effect of mometasone furoate nasal spray (100 mcg total daily dose) on growth velocity has been conducted in pediatric patients 3 to 9 years of age with allergic rhinitis. no statistically significant effect on growth velocity was observed for mometasone furoate nasal spray compared to placebo following one year of treatment. no evidence of clinically relevant hpa axis suppression was observed following a 30-minute cosyntropin infusion. the potential of mometasone furoate nasal spray to cause growth suppression in susceptible patients or when given at higher doses cannot be ruled out. a total of 280 patients above 64 years of age with allergic rhinitis or chronic rhinosinusitis with nasal polyps (age range 64 to 86 years) have been treated with mometasone furoate nasal spray for up to 3 or 4 months, respectively. no observed differences in safety and/or effectiveness in geriatric patients compared to younger adult patients.   concentrations of mometasone furoate appear to increase with severity of hepatic impairment [see clinical pharmacology (12.3)] .

United States - English - NLM (National Library of Medicine)

golden state medical supply, inc. - mometasone (unii: 8hr4qj6dw8) (mometasone - unii:8hr4qj6dw8) - mometasone 50 ug - mometasone furoate nasal spray is indicated for the prophylaxis of the nasal symptoms of seasonal allergic rhinitis in adult and pediatric patients 12 years and older. mometasone furoate nasal spray is indicated for the treatment of chronic rhinosinusitis with nasal polyps in adult patients 18 years of age and older. mometasone furoate nasal spray is contraindicated in patients with known hypersensitivity to mometasone furoate or any of its ingredients  [see warnings and precautions ( 5.3), description ( 11)]. risk summary mometasone is minimally absorbed systemically following nasal use, and maternal use is not expected to result in fetal exposure to the drug. available data from observational studies of mometasone use in pregnant women are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. in animal reproduction studies with pregnant mice, rats, or rabbits (subcutaneous, subcutaneous/topical dermal/oral, and topical dermal/oral, respectively), mometasone furoate caused increased fetal malformations and decreased fetal survival and growth following administration of doses that produced exposures approximately 1/3 to 8 times the maximum recommended human dose (mrhd) on a mcg/m 2 or auc basis [see data]. however, experience with oral corticosteroids suggests that rodents are more prone to teratogenic effects from corticosteroid exposure than humans. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.  data animal data in an embryofetal development study with pregnant mice dosed throughout the period of organogenesis, mometasone furoate produced cleft palate at a dose less than the maximum recommended daily intranasal dose (mrdid) (on a mcg/m 2 basis with maternal subcutaneous doses of 60 mcg/kg and above) and decreased fetal survival at approximately 2 times the mrdid (on a mcg/m 2 basis with a maternal subcutaneous dose of 180 mcg/kg). no toxicity was observed with a dose that produced an exposure less than the mrdid (on a mcg/m 2 basis with maternal topical dermal doses of 20 mcg/kg and above).  in an embryofetal development study with pregnant rats dosed throughout the period of organogenesis, mometasone furoate produced fetal umbilical hernia at exposures approximately 10 times the mrdid (on a mcg/m 2 basis with maternal topical dermal doses of 600 mcg/kg and above) and delays in fetal ossification at a dose approximately 6 times the mrdid (on a mcg/m 2 basis with maternal topical dermal doses of 300 mcg/kg and above).  in another reproductive toxicity study, pregnant rats were dosed with mometasone furoate throughout pregnancy or late in gestation. treated animals had prolonged and difficult labor, fewer live births, lower birth weight, and reduced early pup survival at a dose less than the mrdid (on a mcg/m 2 basis with a maternal subcutaneous dose of 15 mcg/kg). there were no findings at a dose less than the mrdid (on a mcg/m 2 basis with a maternal subcutaneous dose of 7.5 mcg/kg).  embryofetal development studies were conducted with pregnant rabbits dosed with mometasone furoate by either the topical dermal route or oral route throughout the period of organogenesis. in the study using the topical dermal route, mometasone furoate caused multiple malformations in fetuses (e.g., flexed front paws, gallbladder agenesis, umbilical hernia, hydrocephaly) at doses approximately 6 times the mrdid (on mcg/m 2 basis with maternal topical dermal doses of 150 mcg/kg and above). in the study using the oral route, mometasone furoate caused increased fetal resorptions and cleft palate and/or head malformations (hydrocephaly and domed head) at a dose approximately 30 times of the mrdid (on a mcg/m 2 basis with a maternal oral dose of 700 mcg/kg). at approximately 110 times the mrdid (on a mcg/m 2 basis with a maternal oral dose of 2800 mcg/kg), most litters were aborted or resorbed. no effects were observed at a dose approximately 6 times the mrdid (on a mcg/m 2 basis with a maternal oral dose of 140 mcg/kg). risk summary there are no available data on the presence of mometasone furoate nasal spray in human milk, the effects on the breastfed child, or the effects on milk production. however, mometasone is minimally absorbed systemically by the mother following nasal use, and breastfeeding is not expected to result in exposure of the infant to mometasone. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for mometasone furoate nasal spray and any potential adverse effects on the breastfed infant from mometasone furoate nasal spray or from the underlying maternal condition.  the safety and effectiveness of mometasone furoate nasal spray for prophylaxis of the nasal symptoms of seasonal allergic rhinitis in pediatric patients 12 years of age and older have been established [see adverse reactions ( 6.1) and clinical studies ( 14.1)]. use of mometasone furoate nasal spray forthis indication is supported by evidence from controlled trials in adult and pediatric patients 12 years of age and older [see clinical studies ( 14.1)].  the safety and effectiveness of mometasone furoate nasal spray for the treatment of chronic rhinosinusitis with nasal polyps in pediatric patients less than 18 years of age have not been established. effectiveness was not demonstrated in one 4-month trial conducted to evaluate the safety and efficacy of mometasone furoate nasal spray in the treatment of chronic rhinosinusitis with nasal polyps in pediatric patients 6 to 17 years of age. the primary objective of the study was to evaluate safety; efficacy parameters were collected as secondary endpoints. a total of 127 patients with chronic rhinosinusitis with nasal polyps were randomized to placebo or mometasone furoate nasal spray 100 mcg once or twice daily (patients 6 to 11 years of age) or 200 mcg once or twice daily (patients 12 to 17 years of age). the results of this trial did not support the efficacy of mometasone furoate nasal spray in the treatment of chronic rhinosinusitis with nasal polyps in pediatric patients. the adverse reactions reported in this trial were similar to the adverse reactions reported in patients 18 years of age and older with chronic rhinosinusitis with nasal polyps. effect of growth controlled clinical studies have shown nasal corticosteroids may cause a reduction in growth velocity in pediatric patients. this effect has been observed in the absence of laboratory evidence of hypothalamic-pituitary-adrenal (hpa) axis suppression, suggesting that growth velocity is a more sensitive indicator of systemic corticosteroid exposure in pediatric patients than some commonly used tests of hpa axis function. the long-term effects of this reduction in growth velocity associated with nasal corticosteroids, including the impact on final adult height, are unknown. the potential for "catch up" growth following discontinuation of treatment with nasal corticosteroids has not been adequately studied. the growth of pediatric patients receiving nasal corticosteroids, including mometasone furoate nasal spray, should be monitored routinely (e.g., via stadiometry). the potential growth effects of prolonged treatment should be weighed against clinical benefits obtained and the availability of safe and effective noncorticosteroid treatment alternatives. to minimize the systemic effects of nasal corticosteroids, including mometasone furoate nasal spray, each patient should be titrated to his/her lowest effective dose. a clinical study to assess the effect of mometasone furoate nasal spray (100 mcg total daily dose) on growth velocity has been conducted in pediatric patients 3 to 9 years of age with allergic rhinitis. no statistically significant effect on growth velocity was observed for mometasone furoate nasal spray compared to placebo following one year of treatment. no evidence of clinically relevant hpa axis suppression was observed following a 30-minute cosyntropin infusion. the potential of mometasone furoate nasal spray to cause growth suppression in susceptible patients or when given at higher doses cannot be ruled out. a total of 280 patients above 64 years of age with allergic rhinitis or chronic rhinosinusitis with nasal polyps (age range 64 to 86 years) have been treated with mometasone furoate nasal spray for up to 3 or 4 months, respectively. no observed differences in safety and/or effectiveness in geriatric patients compared to younger adult patients.   concentrations of mometasone furoate appear to increase with severity of hepatic impairment [see clinical pharmacology (12.3)] .